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1114-202 Effects of Beta-Adrenergic Blockade in Pediatric Marfan 
Syndrome
Karina M. Carlson, Pamela E. Ganz, E. O. Smith, William Craigen, Stephanie M. Ware, 
Susan Fernbach, John W. Belmont, Steven R. Neish, Jeffrey A. Towbin, Texas Children's 
Hospital, Houston, TX
Background: Pediatric patients with Marfan syndrome are often treated with beta-adren-
ergic blockade, though few studies have evaluated these patients’ response to therapy.
Additionally, the impact of age and concomitant treatment with other medications, such
as stimulant medication for attention deficit hyperactivity disorder, is unknown.
Methods: 100 consecutive patients with Marfan syndrome evaluated at our institution
between 1992 and 2002 were studied. Age at diagnosis, diagnostic criteria, echocardio-
graphic measurements of the aorta, pulmonary arteries, mitral valve and ventricular func-
tion, cardiovascular and other medications, height, weight, heart rate, blood pressure at
each visit, and any significant cardiovascular events were recorded. The patients were
divided into groups based on treatment with beta-blockade and age at diagnosis, and
compared using t-test and analysis of variance.
Results: 84 patients had serial evaluations by echocardiography (mean age 9.9 yrs,
range 1 wk-21 yrs). 61/84 (75%) were treated with beta-blocker therapy. 74/84 (88%) had
aortic root dilation at presentation, with a mean Z score of 3.4 (range 0.3-10.4). There
was a significantly slower rate of dilation of the aortic annulus, aortic root, sinotubular
junction, pulmonary valve annulus and main pulmonary artery in those patients treated
with beta-blockers (all p<0.05). Patients treated with beta-blockade had lower heart rate
and systolic blood pressure (p<0.01). Beta-blocker agent used, gender, treatment with
stimulant medications, and competitive sports participation did not affect the rate of dila-
tion. There was a faster rate of aortic root dilation among patients who developed
ascending aortic aneurysms requiring root replacement (p<0.01).
Conclusion: Beta-blocker therapy reduces the rate of progression of great vessel dila-
tion in pediatric patients with Marfan syndrome. The management of pediatric Marfan
syndrome with aortic root dilation should include pharmacologic beta-blockade as stan-
dard therapy. Patients may be treated with stimulant medication as needed without wors-
ening the progression of their disease.
1114-203 Noonan Syndrome: Cardiovascular Outcomes
Dan Sorajja, John Belmont, William Craigen, Stephanie Ware, Steven Neish, Susan 
Fernbach, Jeffrey A. Towbin, Baylor College of Medicine, Houston, TX, Texas Children's 
Hospital, Houston, TX
Background: Noonan syndrome is a common autosomal dominant condition character-
ized by dysmorphic features, short stature, typically normal development and intellect,
and cardiovascular abnormalities.The heart-related abnormalities include pulmonic
stenosis (PS), hypertrophic cardiomyopathy (HCM), along with septal defects (ASD/
VSD). A gene for Noonan syndrome has been identified as PTPN11 on chromosome
12q24.2 – q24.3, but the cardiovascular genotype-phenotype correlations appear to iden-
tify only those with pulmonic stenosis as a clinical phenotype. In this study our goal was
to determine the frequency of heart-related disease, types of cardiac abnormalities, and
disease-based outcomes.
Materials/Methods: Consecutive patients were evaluated retrospectively using the
Texas Children’s Hospital and Pediatric Cardiology Databases. All subjects were ana-
lyzed for cardiac anomaly, phenotypic subtype, and clinical outcome.
Results: 28 consecutive subjects with Noonan syndrome were identified and evaluated,
including 17 males (61%) and 11 females (39%). The age at diagnosis ranged between
0.3 to 186 months (mean = 45 months). On Echocardiogram 26/28 (93%; 16 males, 10
females) had heart disease, including 50% with PS (n=13), 38% with HCM (n=10). 29%
(n=8) of patients had an ASD. Of these, 75% (n=6) occurred with PS and 50%(n=4)
occurred with HCM. 7% (n=2) had a VSD with 100% of them occurring with both PS and
HCM. On ECG, 82% (n=23) were read as abnormal, and on chest x-ray, 43% (n=12) had
cardiomegaly or increased pulmonary vascular markings. Of the 28 patients, 4% (n=1)
died, and the cause was attributed to CHF (age of death = 8 days).
Conclusions: In a high percentage of children with Noonan syndrome, heart disease is
identified, including pulmonic stenosis in 50% of cases, and hypertrophic cardiomyopathy
in 38%. Despite significant heart disease, the mortality rate is low and the children can
lead normal lives and have excellent long-term outcomes.
1114-204 Regression of Left Ventricular Dilation in Children With 
Restrictive Ventricular Septal Defects With Initial Large 
Volume Overload
Mahnaz Tabibian, Charles S. Kleinman, Thomas J. Starc, Beth F. Printz, Patrick Flynn, 
Daphne Hsu, Welton M. Gersony, Columbia University College of Physicians and 
Surgeons, New York, NY, Weil-Cornell Medical Center, New York, NY
Background: The role of surgery in the management of a restrictive ventricular septal
defect (VSD) with left ventricular (LV) volume overload and no congestive heart failure
(CHF), failure to thrive (FTT) or pulmonary hypertension (PH) is controversial. The Natu-
ral History Study (NHS) demonstrated normal survival in such patients (pts) without oper-
ation; however, some centers close these defects, presumably to avoid late
consequences of LV volume overload. Given the NHS results and paucity of reports of
late LV failure in adult pts, we hypothesize that LV dilation would regress among pts with
a VSD and marked LV enlargement unassociated with CHF, FTT or PH.
Methods. Clinical and echocardiographic records were retrospectively reviewed to iden-
tify pts with a moderate to large VSD without CHF, FTT, or PH. Pts who presented with an
LV end-diastolic dimension (LVED) z score >1 and were followed for a period >2 years
were included .
Results. 70 pts were identified; mean age at baseline echocardiography was 4.9 ± 3.9
years (yrs), mean follow-up was 7.3 ± 4.2 yrs. LVED z score decreased significantly dur-
ing the follow-up period (p<.001), irregardless of age at presentation. LVED z score was
>2 in 33/70 pts. In this subgroup with a mean follow-up of 7.8 ± 4 years (range 2.8-22),
LVED z score decreased significantly from 3 ± 0.6 to 1.2 ± 1.3 (p <0.01), see graph
below.Conclusions: In patients with restrictive VSD and no CHF, FTT, or PH, LV dimen-
sions normalize over time, even in patients with significant volume overload.
1114-205 Racial Differences in Blood Pressure Response in 
Children With Hypertension Treated With Fosinopril
Joseph D. Kay, Rakhi Kilaru, Katherine Berezny, David Deitchman, Jennifer S. Li, Duke 
University, Durham, NC
Background:
Although it is well established that responses to ACE inhibitors vary with race, no such
studies have been performed in children.
Methods:
A total of 253 children (152 white, 52 black, 5 Asian, 35 Hispanic, 1 Native American, 8
other) ages 6–16 years were enrolled at 62 clinical sites in the United States, Russia, and
Israel, with 238 completing the trial. Participants had either hypertension (systolic or dias-
tolic blood pressure [BP] > the 95th percentile for age and height on 3 separate occa-
sions) or high normal BP (> the 90th percentile) with an associated condition requiring
antihypertensive therapy. Patients were randomly assigned in a double-blind fashion to
receive either 0.1 mg/kg/day, 0.3 mg/kg/day, or 0.6 mg/kg/day of fosinopril. BP was mea-
sured weekly for 4 weeks. They were then randomly assigned to continue study drug or
receive placebo for a maximum of 2 weeks.
Results:
After adjusting for baseline BP and body surface area, there was no significant dose
response in nonblack children. Nonblacks who received the low, medium, and high doses
of fosinopril all had a mean decrease of 12 mm Hg in their systolic BP (p=0.957). Blacks
who received the low dose had a mean 5 mm Hg decrease in systolic BP, whereas those
who received the high dose had a mean 13 mm Hg decrease in systolic BP (p=0.0277,
Table).
Conclusion:
Although fosinopril was effective in treating hypertension in both black and nonblack chil-
dren, black children tended to require a higher dose per body weight in order to achieve a
similar BP response.
Racial Difference in BP Effect of Fosinopril
0.1 mg/kg 0.3 mg/kg 0.6 mg/kg
NONBLACKS
No. Patients 64 67 59
 Baseline SBP (mean, mmHg) 133.9(10.9) 131.8(11.3) (10.6)
 Change in SBP, mmHg (SE) -11.5(1.2) -11.6(1.2) -11.6(1.3)
 95% CI -14.0, -9.1 -14.0, -9.2 -14.2, -9.1
 P-value(ANOVA) 0.9570
BLACKS
 No. Patients 9 19 20
Baseline SBP (mean, mmHg) 136.4(13.1) 137.8(13.6) 133.5(10.8)
Change in SBP, mmHg (SE) -4.7(2.9) -11.0(2.0) -12.8(1.9)
95% CI -10.6, 1.2 -15.1, -6.9 -16.8, -8.9
P-value(ANOVA) 0.0277
